Found: 6
Select item for more details and to access through your institution.
Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study.
- Published in:
- Clinical Colorectal Cancer, 2010, v. 9, n. 5, p. 282, doi. 10.3816/CCC.2010.n.041
- By:
- Publication type:
- Article
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 2, p. e261, doi. 10.1002/onco.13591
- By:
- Publication type:
- Article
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.
- Published in:
- Oncologist, 2016, v. 21, n. 3, p. 292, doi. 10.1634/theoncologist.2015-0279
- By:
- Publication type:
- Article
Reduced Incidence of Infusion-Related Reactions in Metastatic Colorectal Cancer During Treatment With Cetuximab Plus Irinotecan With Combined Corticosteroid and Antihistamine Premedication.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 7, p. 1827, doi. 10.1002/cncr.24945
- By:
- Publication type:
- Article
Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2019, v. 15, n. 4, p. 225, doi. 10.1111/ajco.13154
- By:
- Publication type:
- Article
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 2, p. 255, doi. 10.1007/s11523-014-0336-7
- By:
- Publication type:
- Article